Glaukos Corporation Common Stock (NY:GKOS)

164.01 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Sight Sciences' Q4 Earnings, FY22 Guidance Beat Street View ↗

March 25, 2022

Sight Sciences Inc (NASDAQ: SGHT) has treated the first patient in the TRIDENT trial evaluating OMNI Surgical System compared to Glaukos Corp's (NYSE...

Via Benzinga

Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy

March 14, 2022

From Glaukos Corporation

Via Business Wire

Glaukos: Q4 Earnings Insights ↗

February 22, 2022

Glaukos (NYSE:GKOS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Glaukos...

Via Benzinga

Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results

February 22, 2022

From Glaukos Corporation

Via Business Wire

Earnings Scheduled For February 22, 2022 ↗

February 22, 2022

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu...

Via Benzinga

Analyst Ratings For Glaukos ↗

January 19, 2022

Glaukos (NYSE:GKOS) has observed the following analyst ratings within the las...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Glaukos Announces Executive Leadership Changes

February 07, 2022

From Glaukos Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022 ↗

February 03, 2022

Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago...

Via Benzinga

Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22

February 01, 2022

From Glaukos Corporation

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 12, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022 ↗

January 19, 2022

Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo...

Via Benzinga

The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award ↗

January 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen...

Via Benzinga

Glaukos' iDose TR Shows Sustained Reduction In Ocular Pressure, Favorable Safety Profile ↗

January 12, 2022

Ophthalmic medical company Glaukos Corporation (NYSE: GKOS) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The...

Via Benzinga

Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia

January 11, 2022

From Glaukos Corporation

Via Business Wire

Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease

January 11, 2022

From Glaukos Corporation

Via Business Wire

Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study

January 11, 2022

From Glaukos Corporation

Via Business Wire

The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs ↗

January 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name...

Via Benzinga

A Peek Into The Markets: US Stock Futures Higher; All Eyes On Jobs Report ↗

January 07, 2022

Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of the key jobs data for December. Investors are awaiting earnings results from Acuity Brands,...

Via Benzinga

5 Stocks To Watch For January 7, 2022 ↗

January 07, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects Acuity Brands, Inc. (NYSE: AYI) to report quarterly earnings at $2.41 per share on revenue of $...

Via Benzinga

Glaukos Announces FDA 510(k) Clearance of iPRIME™

January 06, 2022

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

December 29, 2021

From Glaukos Corporation

Via Business Wire

Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

December 20, 2021

From Glaukos Corporation

Via Business Wire

Glaukos Corp (GKOS) FY 2021 Earnings Call Transcript ↗

November 30, 2021

GKOS earnings call for the period ending November 29, 2021.

Via The Motley Fool

Topics Earnings

Glaukos Announces Participation in Upcoming Investor Conferences

November 19, 2021

From Glaukos Corporation

Via Business Wire

FDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular Pressure ↗

November 11, 2021

The FDA has signed off Sight Sciences Inc's (NASDAQ: SGHT) clinical study to assess investigational higher volume OMNI device to perform canal viscodilation...

Via Benzinga

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting

November 11, 2021

From Glaukos Corporation

Via Business Wire

Glaukos Corp (GKOS) Q3 2021 Earnings Call Transcript ↗

November 07, 2021

GKOS earnings call for the period ending October 31, 2021.

Via The Motley Fool

Topics Earnings

Glaukos Corporation Announces Third Quarter 2021 Financial Results

November 04, 2021

From Glaukos Corporation

Via Business Wire

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.